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Abstract
Background: The possibility that autologous NK cells could serve as an effective treatment modality for solid
tumors has long been considered. However, implementation is hampered by (i) the small number of NK cells in
peripheral blood, (ii) the difficulties associated with large-scale production of GMP compliant cytolytic NK cells, (iii)
the need to activate the NK cells in order to induce NK cell mediated killing and (iv) the constraints imposed by
autologous inhibitory receptor-ligand interactions. To address these issues, we determined (i) if large numbers of
NK cells could be expanded from PBMC and GMP compliant cell fractions derived by elutriation, (ii) their ability to
kill allogeneic and autologous tumor targets by direct cytotoxitiy and by antibody-mediated cellular cytotoxicity
and (iii) defined NK cell specific receptor-ligand interactions that mediate tumor target cell killing.
Methods: Human NK cells were expanded during 14 days. Expansion efficiency, NK receptor repertoire before and
after expansion, expression of NK specific ligands, cytolytic activity against allogeneic and autologous tumor
targets, with and without the addition of chimeric EGFR monoclonal antibody, were investigated.
Results: Cell expansion shifted the NK cell receptor repertoire towards activation and resulted in cytotoxicity
against various allogeneic tumor cell lines and autologous gastric cancer cells, while sparing normal PBMC.
Blocking studies confirmed that autologous cytotoxicity is established through multiple activating receptor-ligand
interactions. Importantly, expanded NK cells also mediated ADCC in an autologous and allogeneic setting by
antibodies that are currently being used to treat patients with select solid tumors.
Conclusion: These data demonstrate that large numbers of cytolytic NK cells can be generated from PBMC and
lymphocyte-enriched fractions obtained by GMP compliant counter current elutriation from PBMC, establishing the
preclinical evidence necessary to support clinical trials utilizing autologous expanded NK cells, both directly and in
combination with monoclonal antibodies in future cell-based immunotherapy in select solid tumors.
Background
Natural killer cells (NK) were identified more than 30
years ago as a population of lymphokine activated killer
cells that showed the ability to kill tumor cells in vitro
in the absence of prior immune sensitization of the host
[1-4]. Over the ensuing years, much has been learned
about regulation of their biologic activity and, in parti-
cular, their potential use as an immunotherapeutic mod-
ality in cancer [5].
It has become clear that the biologic activity of NK
cells is controlled by a complex repertoire of surface
receptors which, upon engagement by ligands on a tar-
get cell, signal either an inhibitory or activating response
[6]. The major inhibitory and activating receptors are
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noglobulin-like receptors (KIRs) and in an autologous
environment, inhibition of NK cell cytotoxic activity is
dominant and governed by epitopes on self HLA class I
alleles. In general, cytotoxic activity of NK cells is trig-
gered when the target cell lacks expression of some or
all HLA class I molecules; the basis for the “missing
self” hypothesis [7].
Recognizing the possibility that NK cells have the abil-
ity to kill tumors that lack expression of the inhibitory
HLA class I alleles, investigators have reported signifi-
cant antitumor responses in clinical settings of allo-
geneic stem cell transplantation. Importantly, clinical
effects are demonstrated when inhibitory effects are
bypassed by utilizing haplo-identical NK cells and best
results are achieved when, in addition, KIR-ligand mis-
matched NK cells are selected [8,9]. In turn, this
approach requires extensive donor screening and careful
depletion of allogeneic T cells from the NK cell product
before administration to the host in order to avoid the
risk of graft-versus-host disease (GvHD) [10].
The possibility that infusion of autologous NK cells
could serve as an effective treatment modality for solid
tumors has long been considered [11]. However, imple-
mentation is hampered by (i) the small number of NK
cells in peripheral blood that could be isolated relative
to the number of cells that would be required to be
effective and the difficulties associated with large-scale
production of cytolytic NK cells in compliance with
Good Manufacturing Practices (GMP), (ii) the need to
activate the NK cells in order to induce NK cell
mediated killing of a resident tumor and (iii) the con-
straints imposed by autologous inhibitory receptor-
ligand interactions.
The first issue has been addressed in a number of
reports that demonstrate that large numbers of NK cells
could be expanded from CD56
+ cells isolated from per-
ipheral blood mononuclear cells (PBMC) obtained from
healthy individuals and patients with hematological
malignancies and solid tumors. Expansion was achieved
by short term culture with cytokines alone, by cytokines
and co-culture with irradiated feeder cells consisting of
EBV transformed lymphoblastoid cell lines or cytokines
and co-culture with K562 cells that had been transfected
with and expresses cell membrane-bound IL-15 and 4-
1BBL [12-16]. In most instances, these expanded cells
were generated from NK cells (CD56
+CD3
-)i s o l a t e d
from peripheral blood using magnetic beads. The
expanded NK cells were highly cytotoxic when tested
against variety of target cells that consisted primarily of
allogeneic cancer cell lines established from hematologic
malignancies [12,17].
In addition, a GMP compliant and closed system has
successfully been established for the enrichment of
monocytes from PBMC using counter current elutria-
tion [18]. Besides a highly enriched population of mono-
cytes, lymphocyte-enriched fractions are also obtained.
Currently, clinical studies are ongoing utilizing elutria-
tion derived monocytes for large-scale generation of
dendritic cells in order to treat a variety of metastatic
cancers.
The objectives of this study were to evaluate if the
aforementioned strategies could be combined in order
to expand large numbers of NK cells from PBMC from
normal individuals and patients with various solid
tumors. Furthermore, the possibility to expand NK cells
from lymphocyte-enriched cell fractions derived from
PBMC by elutriation rather than utilizing isolated CD56
+ cells as the starting cell population was determined. In
addition, cytolytic allogeneic and autologous activity by
direct cytotoxicity as well as antibody-mediated cellular
cytotoxicity and NK specific receptor-ligand interactions
that mediate target cell killing were defined.
We confirmed that large quantities of cytotoxic NK
cells can be expanded from PBMC in the presence of
K562 cells expressing membrane-bound IL-15 and 4-
1BBLigand from normal individuals and patients with
various solid tumors. Ex-vivo expansion tended to alter
the balance of NK cell receptor expression towards
those that activate and mediate cytotoxicity. This activity
resulted in cytotoxicity against various allogeneic tumor
targets and more importantly, against autologous-
derived gastric tumor targets. Blocking studies identified
multiple activating receptor-ligand interactions that
would be predicted to mediate NK cell cytotoxicity.
Moreover, these activating receptor-ligand interactions
were operative in antibody-dependent cellular cytotoxi-
city (ADCC) in an allogeneic and autologous setting.
Importantly, as a mean for future clinical translation,
GMP compliant cytolytic NK cells could efficiently be
expanded from lymphocyte-enriched cell fractions
obtained from PBMC by counter current elutriation.
Our studies demonstrate that human NK cells acquire
cytolytic activity against autologous gastric tumor cells
after ex-vivo expansion and suggest a therapeutic poten-
tial for autologous expanded NK cells, both directly and
in combination with monoclonal antibodies in future
cell-based immunotherapy.
Methods
Cells and Cell Fractions
Human blood samples were purchased (BRT Labora-
tories, Baltimore, MD) and whole peripheral blood
mononuclear cells (PBMC) were isolated using density-
gradient centrifugation. Using leukapheresis products
purchased from the same source, the constitutive cell
populations were fractionated by continuous-counter-
flow elutriation following protocols established by the
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This instrument uses continuous counter-flow elutria-
tion technology to separate cells fractions based primar-
i l yb ys i z ea n ds e c o n d a r i l yb ys p e c i f i cg r a v i t y .I nb r i e f ,
the leukapheresis product was loaded via an inlet pump
into a constantly rotating (2400 rpm) elutriation cham-
ber. Based on centrifuge speed and cell density, five elu-
triated cell fractions were collected. PBMC and various
elutriated cell fractions were viably frozen in RPMI-1640
(Invitrogen Corp., Grand Island, NY) supplemented with
20% human AB serum (Gemini Bio-Products, Wood-
land, CA) and 10% Dimethylsulfoxide (Sigma, St. Louis,
MO) using an automated cell freezer (Gordinier Electro-
nics, Roseville, MI) and stored in the vapor phase of
liquid nitrogen until used.
The myeloid cell line K562, prostate cancer cell lines
LNCaP, PC-3 and DU-145 and breast cancer cell line
MCF-7 were available in our laboratory. The lung can-
cer cell line H358 was kindly provided by Dr. S.
Ostrand-Rosenberg (Department of Biological Sciences,
University of Maryland Baltimore County, Catonsville,
MD) and the Head and Neck cancer cell line TU-167
was kindly provided by Dr. S. Strome (Department of
Otorhinolaryngology-Head and Neck Surgery, University
of Maryland, Baltimore, MD).
With patient consent and under approval of the Insti-
tutional Review Board, peripheral blood mononuclear
cells were obtained from 2 patients with gastric cancer
undergoing treatment at the Tokyo Clinic and Research
Institute. Cell lines (tumor 1 and tumor 2) were estab-
lished from biopsies of metastatic gastric tumor lesions
from the respective patients. All tumor cell lines were
cultured in RPMI 1640 supplemented with 10% Fetal
Bovine Serum, 1% P/S and 1% Glutamax-1 (cRPMI).
Ex-vivo NK cell expansion
NK cells were expanded from PBMC as previously
described with some minor modifications [12]. In brief,
PBMC (1.5 × 10
6) were incubated with irradiated
(14,000 rad) K562-mbIL15-41BBL cells (10
6)i na2 4 -
well tissue culture plate in the presence of 200 IU/ml
human IL-2 (R&D Systems Inc) in cRPMI. Half of the
culture medium was replaced every 2-3 days with fresh
culture medium for the first 6 days. After 6 days of
expansion, cells were harvested, washed, counted and
re-cultured at a starting cell density of 1 × 10
5-3 × 10
5/
ml in T-25 or T-75 culture flasks in cRPMI supplemen-
ted with IL-2. Cells were expanded for and additional 8
days. Additional cRPMI was added to the flasks if neces-
sary based on cell density.
Flow Cytometry
Cell surface expression was determined before and after
14 days of cell expansion by staining with directly
conjugated mouse anti-human mAb’sa g a i n s tC D 3 ,
CD56, abTCR, gδTCR, HLA class I, HLA-DR, Fas, Fas-
l i g a n d ,K L R D 1 ,N K G 2 a ,K I R 3 D L 1 ,I L T 2 ,C D 6 2 L ,
KIR3DL2/3, NKG2d, DNAM-1, NKp46, NKp44 and
NKp30 (BD Biosciences). Gates were set around NK
cells which were defined as CD3
-CD56
+ cells. Surface
expression of NK cell ligands was determined on both
autologous gastric tumor cell lines and included directly
conjugated mouse anti-human nectin-2, PVR, MIC A/B,
Fas, HLA class I, HLA class II, HLA-G and purified
mouse anti-human HLA-E, ULPB-1, ULBP-2 and
ULBP-3. For EGFR-mediated ADCC, gastric tumors
were stained with mouse anti-human EGFR mAb.
Mouse IgGs were used as isotype controls and purified
mAbs were secondarily stained with FITC labelled goat
anti-mouse mAb. A minimum of 10000 events were
acquired using a BD™ LSR II flow cytometer. Data was
analyzed with BD™ FACS DIVA Software.
Cytotoxicity assays
Cytolytic NK cell activity was measured by 4 hour chro-
mium 51 (
51Cr)-release assays as previously described
[19]. K562 cells were included as target cells in all cyto-
toxicity assays to assess overall cytotoxicity performance
(data not shown). Expanded day 14 cells were purified
into separate populations of NK cells (CD3
-CD56
+)a n d
NKT/T (CD3
+CD56
+/CD3
+CD56
-) cells using MACS
human CD3 microbeads and non-expanded NK cells
were purified from PBMC using a MACS human NK
cell isolation kit. (Miltenyi Biotec Inc). Cell purity was
determined to be >92% and 95% respectively. To deter-
mine ADCC, 10 μg/ml human IgG1 (huIgG1, Sigma-
Aldrich Corp, St. Louis, MO, USA) or Cetuximab (Uni-
versity of Maryland Marlene and Stewart Greenebaum
Cancer Center Pharmacy) was added to defined wells.
Purified mouse IgG1, mouse anti-DNAM-1, NKp46,
NKp44, NKp30 or all four together (all at 10 μg/ml)
were added to defined wells during 4 hours of cytotoxi-
city in order to assess specific activating NK cell recep-
tor-tumor ligand interactions. Reduction in cytotoxicity
was calculated based on percentage cytotoxicity in the
presence of indicate blocking mAb(s) versus percentage
cytotoxicity in the presence of mouse control mAb. The
% reduction in ADCC was calculated with percentage
cytotoxicity in the presence of human IgG1 set at 100%.
To minimize changes that may occur when cell lines
are established from primary tumors, the gastric cell
lines used in these studies were cultured for less than
10 passages after isolation from the primary tumor
tissue.
Statistics
Paired two-tailed Student’s t tests were used to calculate
p values. P < 0.05 was considered to be significant.
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Cytotoxic NK cells are efficiently expanded from PBMC
from normal individuals and patients with various solid
tumors without the need of primary enrichment
protocols
To achieve large-scale expansion of human NK cells,
PBMC were co-cultured in a 1 to 1.5 ratio with lethally
irradiated K562 cells expressing membrane-bound IL-15
and 4-1BBLigand (K562-mbIL15-4-1BBL) in culture
media containing 200 units IL2/ml. After 14 days of cul-
ture, NK cells (CD56
+CD3
- as defined by flow cytome-
try) expanded greater than 2 orders of magnitude from
PBMC (mean 165 fold; range 4-567 fold, n = 6) and cell
products became significantly enriched in NK cells (day
0 with mean 7%, range 3.2%-12.6% versus day 14 with
mean 45.6%, range 7.4%-76.4%; P = 0.0140). At the
same time, NKT cells (CD56
+CD3
+ as defined by flow
cytometry) expanded at an average of 57 fold (range 7-
234), although no significant enrichment (day 0 with
mean 3.8%, range 0.8%-8.1% versus day 14 with mean
11.4%, range 2.3%-17.9%; P = 0.1907) was observed. In
contrast, a significant decrease in T cells (CD3
+ as
defined by flow cytometry) was noted after 14 days of
expansion (day 0 with mean 54.5%, range 39.9%-71.2%
versus day 14 with mean 30.0%, range 4.2%-58.4%; P =
0.0436) with an absolute expansion of 7 fold (range 2-
19). The distribution of NK cells and NKT cells in
PBMC after expansion is shown in Figure 1A.
Importantly, ex-vivo expanded NK cells from healthy
donor PBMC efficiently lysed allogeneic breast-and
prostate-derived tumor targets but not allogeneic or
autologous PBMC (Figure 1B). We did observe that
cytotoxicity was associated with overall expansion effi-
ciency. Specifically, the one donor whose cells expanded
4 fold after 14 days of culture demonstrated an average
of 11.7% cytotoxicity (effector to target ratio 1:10)
against K562 cells whereas donors who expanded an
average of 202 fold (range 34-576; n = 4) possessed an
average of 59.8% cytotoxicity (range 56.0%-65.9%; n = 4)
against K562 cells (data not shown).
Based on CD3 and/or CD56 phenotype, the majority
of cells in the expanded cell products represented NK
cells while a much smaller proportion represented NKT
and T cells (Table 1). To determine if both the NK cells
and NKT/T cells mediated cytolytic activity, the two
populations were isolated by immunomagnetic bead
selection and killing assays against prostate-derived
tumor cell targets were performed. Cytolytic activity was
mediated by NK cells and not NKT cells (Figure 1C).
Interestingly, little to no killing was observed with the
NKT/T cell population even though a subpopulation of
the T cells was confirmed to be gδ-TCR
+ by flow cyto-
metry (data not shown). Although gδ-TCR
+ T cells are
reported to have lytic activity against allogeneic tumor
cells, they first require in vitro activation with isopente-
nyl pyrophosphate (IPP) and IL-2 [20]. Studies are
underway to determine if addition of IPP will expand a
cytolytic gδ-TCR
+ population.
The capacity of K562-mb15-41BBL to stimulate
expansion of NK cells from peripheral blood of healthy
individuals and children with leukemia in remission was
previously demonstrated [12,17]. However, there is little
information in reference to expand NK cells from
PBMC derived from patients with solid tumors. With
informed consent, NK cells were expanded from PBMC
derived from patients with various solid tumors, includ-
ing gastric cancer, lung cancer, colon cancer and hepa-
tocellular cancer. After 14 days of culture, cell products
became significantly enriched in NK cells (day 0 with
mean 23.5%; range 5%-46% versus day 14 with mean
80%; range 60%-95%, n = 6, P = 0.0001 data not
shown). Expansion efficiency was comparable between
PBMC derived from solid tumor patients versus healthy
donor PBMC (mean 316 fold; range 1-1795 with n = 6
versus mean 165 fold; range 4-567 with n = 6, P =
0.6685).
These data suggest that NK cells are efficiently
expanded from PBMC from normal individuals and
more importantly, from patients with various solid
tumors without the need of primary enrichment
protocols.
NK cell expansion turns the receptor balance towards
activation and results in autologous gastric tumor cell
lysis
Human NK cells maintain self tolerance by the expres-
sion of at least one inhibitory receptor specific for auto-
logous HLA class I which prevents cytotoxicity against
autologous cells [21]. To establish cytotoxicity against
autologous target cells, inhibitory signals must be over-
come, either by (i) down-regulation of inhibitory ligands
on the tumor cell, (ii) enhanced expression of activating
receptors on NK cells, (iii) expression of ligands on the
tumor target that activate the NK cell or (iv) a combina-
tion of thereof. Since NK cell activation is affected by
cytokines such as IL-2 and IL-15 [22], we sought to
determine if NK cells expanded from PBMC were phe-
notypically different from non-expanded NK cells (Table
2).
In expanded NK cells from normal individuals, no sig-
nificant change was observed in inhibitory receptors
KIR3DL1 (P = 0.1526), KIR3DL2/3 (P = 0.7858) and the
activating receptor NKG2D (P = 0.1074). In contrast,
activating receptors DNAM-1 (P = 0.0061), NKp46 (P =
0.0161), NKp44 (P = 0.0039) and NKp30 (P = 0.0131)
were significantly increased in expression after 14 days
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NKG2A (P = 0.0118), which both form a complex with
the inhibitory non-classical HLA class I ligand HLA-E
[23,24] were also significantly increased after expansion.
Importantly, expression of the inhibitory receptor ILT2
(P = 0.0142) which recognizes multiple HLA class I
alleles, including non-classical HLA class I, HLA-G [25],
was significantly decreased after expansion.
In order to define the ability of expanded NK cells
derived from patients with solid tumors to kill their
autologous tumors, tumor cell lines were established
from tumor biopsies from two metastatic gastric cancer
patients undergoing immunotherapy at the Tokyo Clinic
and Research Institute. Of note, the expression of inhibi-
tory and activating receptors on expanded NK cells from
the gastric cancer donors were generally not different
from expression on expanded NK cells from normal
donors (Table 2).
Since autologous NK cell cytotoxicity is the net result
of engagement of activating NK cell receptors with acti-
vating target cell ligands, the two gastric tumor cell lines
were first phenotypically characterized for expression of
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Figure 1 Cytolytic NK cells are efficiently expanded from PBMC. In the presence of K562-IL15-41BBL (A) expanded cells become significantly
enriched (P = 0.0307) in NK cells (defined by CD56
+CD3
- cells) after 14 days of culture. Expanded cells were evaluated for cytolytic activity using
4 hour
51Cr release assays. Ex-vivo expanded cells from PBMC (■ donor 1 and △ donor 2), but not freshly purified non-expanded NK cells (◇),
efficiently lysed allogeneic tumor cell lines derived from breast (MCF-7) and prostate (LNCaP) cancers but not allogeneic or autologous PBMC
derived from donor 1 (B). The mean percentage cytotoxicity is shown from triplicate wells. Error bars represent the SD. Lytic activity is likely
mediated by NK cells in the expanded cell population (○) since separation in individual populations of NK cells (◇) and NKT/T cells (△) resulted
in allogeneic cytolytic activity of the expanded cell population and the purified NK cell population. Little lytic activity was observed in the
presence of NKT/T cells alone (C). The mean percentage cytotoxicity is shown from triplicate wells from one representative experiment. Error
bars represent the SD. Experiment shown represents one of three individual experiments with three different donors.
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receptors identified in table 2. While the ligands for
human NKp46, NKp44 and NKp30 are to be defined,
both patient cell lines expressed high levels of the inhibi-
tory ligands HLA class I (75% and 67%, respectively) and
HLA-G (42% and 57%, respectively) and relatively small
amounts of the activation ligands MHC class I chain-
related (MIC) A/B (2% and 1%, respectively), UL16 bind-
ing protein (ULBP)-1 (both 3%), ULBP-3 (both 3%) and
polio-virus receptor (PVR; 8% and 9%, respectively).
Importantly, both cell lines expressed the activating
ligand nectin-2 (both 92%; specific for DNAM-1) which
prompted us to evaluate both cell lines for their sensitiv-
ity against autologous NK cells.
Subsequent 4 hour chromium-release (
51Cr-release)
assays confirmed that gastric tumor cells derived from
both patients were killed by autologous expanded NK
cells (Figure 2A) and not by resting (non-expanded) NK
cells from patient 2. Unfortunately, insufficient numbers
of PBMC from patient 1 were available to isolate and
test resting NK cells.
Since expanded NK cells significantly up-regulated
D N A M - 1 ,N K p 4 6 ,N K p 4 4a n dN K p 3 0 ,w ep e r f o r m e d
blocking studies in order to evaluate the importance of
these activating receptor-ligand interactions in autolo-
gous tumor cell recognition (Figure 2B). As expected,
autologous lytic activity was significantly reduced (P =
0.0111 for patient 1 and P = 0.0001 for patient 2) when
activating receptor-ligand interactions were interrupted
by all four blocking antibodies (mAbs). Specifically, lytic
activity of autologous NK cells from patient 1 was sig-
nificantly reduced in the presence of mAb against
DNAM-1 (P = 0.0309) or NKp30 (P = 0.0056) while
lytic activity of autologous NK cells from patient 2 was
only affected in the presence of mAb against NKp46
(P = 0.003).
Table 1 Cell phenotype and fold expansion after 14 days of expansion
CD3
-CD56
+ NK cells CD3
+CD56
+ NKT cells CD3
+CD56
- T cells
Donor Population Expansion Population Expansion Population Expansion
(%) (fold) (%) (fold) (%) (fold)
1 7.4 4 17.9 31 58.4 4
2 61.7 140 4.2 26 21.2 9
3 68.5 61 3.1 7 23.1 4
4 76.5 183 2.3 12 4.2 2
5 35.6 576 37.2 234 22.1 19
6 23.9 34 3.8 33 51.2 7
Mean: 45.6 165 11.4 57 30.0 7
Range: 7.4-76.5 4-576 2.3-17.9 7-234 4.2-58.4 2-19
Table 2 Phenotypic changes on human NK cells after 14 days of expansion
Healthy donors (n = 6) Patient 1 Patient 2
Day 0 Day 14
Mean (%) Range (%) Mean (%) Range (%) P-value
a, b (%) Day 0 Day 14 Day 0 Day 14
Activating receptors
DNAM-1 83 72-90 94 89-97 0.0335 (↑) 90 97 37 90
NKG2D 83 51-98 96 93-99 0.1074 30 94 87 98
NKp46 68 27-91 87 64-97 0.0161 (↑) 52 95 19 70
NKp44 3 2-5 59 16-93 0.0039 (↑) 0,3 29 0,4 15
NKp30 52 11-93 82 67-97 0.0131 (↑) 7 6 31 57 0
Inhibitory receptors
KLRD1 68 56-82 92 86-95 0.0012 (↑) ND 98 49 95
NKG2A 46 14-67 68 34-89 0.00118 (↑) ND 84 7 8
KIR3DL1 22 10-37 29 17-38 0.1526 ND 21 5 3
KIR3DL2/3 28 9-48 29 14-44 0.7858 ND 35 88 96
LIR1 22 13-37 6 3-9 0.0142 (↓) ND 18 70 44
a Significant differences (P < 0.05) are indicated in bold.
b Arrows indicate significant increase (↑) or significant decrease (↓).
ND; not determined.
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allogeneic target cell lysis by antibody-mediated cellular
cytotoxicity
Over many years, it has been postulated that eradication
of human tumors may best be accomplished by combin-
ing cancer treatments modalities [26,27]. Monoclonal
antibodies that react with cell surface structures
expressed on cancer cells represent the most successful
cancer immunotherapy to date. It is quite clear that
their mechanism of action is, at least partially, due to
NK cell-mediated ADCC [28]. Since expanded NK cells
expressed high levels of CD16 (data not shown), an Fc
receptor that mediates ADCC, we sought to determine
if lytic activity against the gastric tumor cells could be
enhanced in the presence of Cetuximab (Erbitux®), a
chimeric monoclonal antibody that reacts with the
EGFR receptor and is used to treat patients with a vari-
ety of solid tumors [29].
Both gastric tumor cell lines were screened for EGFR
and only one of the two patient tumor cell lines (patient
1) expressed EGFR (Table 2). Subsequent
51Cr-release
assays confirmed that allogeneic and autologous cytolytic
activity is greatly enhanced in the presence of chimeric
anti-EGFR mAb but not in the presence of human IgG1
control antibody (Figure 3A). As expected, the enhance-
ment in cytotoxicity was far more dramatic in the autolo-
gous setting if compared to the allogeneic setting since
allogeneic tumor cells do not maintain self tolerance
through specific inhibitory receptor-ligand interactions.
Importantly, the expression of activating receptors on
the ex-vivo expanded NK cells positively affected overall
cytotoxic activity (Figure 3B) since blocking all four
activating receptors on the NK cell surface decreased
autologous cytotoxicity if compared with control mAb
(P = 0.0176 and P = 0.1019, respectively). These data
suggest that the combined strategy of adoptively trans-
ferred ex-vivo expanded autologous NK cells with infu-
sion of an mAb that is used for cancer immunotherapy
may provide clinical benefit for the treatment of select
human solid tumors. To extend these observations, we
are attempting to establish cell lines from other solid
tumors where PBMC would be available to test NK
expansion and direct cytotoxicity and ADCC capability.
NK cells are efficiently expanded from lymphocyte-
enriched cell fractions obtained from PBMC by counter
current elutriation
A GMP compliant system has successfully been estab-
lished for the enrichment of monocytes from PBMC
using an Elutra cell separator. In this closed system,
PBMC are fractionated by centrifugal elutriation and
five cell fractions are obtained. In general, these frac-
tions consist of platelets (fraction 1), erythrocytes mixed
with lymphocytes (fraction 2), lymphocytes (fraction 3),
lymphocytes mixed with monocytes (fraction 4) and
mainly monocytes (fraction 5) as demonstrated in Figure
4 (n = 11). Current clinical cellular therapy protocols
use monocytes obtained from elutriated fraction 5 to
generate dendritic cells for cancer immunotherapy while
the cells from fractions 2, 3 and 4 are usually “archived”
in liquid nitrogen. As a means to facilitate clinical trans-
lation, we explored the possibility of these GMP compli-
ant cell fractions to serve in future NK cell-based
immunotherapy studies. PBMC and separate elutriated
cell fractions were expanded with the aforementioned
expansion strategy. After 14 days of culture in the pre-
sence of K562-mbIL15-41BBL cells and exogenous IL-2,
NK cells expanded greater than two orders of magni-
tude from PBMC (mean 165 fold; range 4-567 fold with
n = 6, data not shown), elutriated cell fraction 2 (mean
209 fold; range 3-615 fold with n = 3, data not shown),
elutriated cell fraction 3 (mean 131 fold; range 4-339
fold with n = 3, data not shown) and elutriated cell frac-
tion 4 (mean 91 fold; range no expansion-358 fold with
n = 4, data not shown). Importantly, expanded cells
from PBMC and separate elutriated cell fractions
became significantly enriched in NK cells and lysed allo-
geneic prostate-derived tumor cell lines in a similar
fashion (Figure 5A-B). Thus, these data show that large
quantities of cytolytic NK cells can be expanded from
various elutriated cell fractions collected with the GMP
compliant Elutra system.
Discussion
The use of NK cells as a cancer treatment modality in
the absence of allogeneic stem cell transplant requires
Table 3 Characterization of NK cell ligands on gastric
tumor cells
Patient 1 (N = 2) Patient 2 (N = 3)
Mean Range Mean Range
Inhibitory ligands
HLA class 1 75% 71%-80% 67% 30%-97%
HLA-E 1% 0%-1% 2% 1%-3%
HLA-G 42% 28%-56% 57% 30%-82%
Activating ligands
PVR 8% 3%-14% 9% 3%-18%
Nectin-2 92% 87%-98% 92% 87%-97%
MIC A/B 2% 1%-2% 1% 0%-1%
ULBP-1 3% 2%-4% 3% 2%-4%
ULBP-2 62% 60%-65% 67% 51%-76%
ULBP-3 3% 3%-4% 3% 2%-4%
Other
Fas 36% 21%-50% 95% 88%-99%
EGFR 95% 93%-98% 18% 7%-29%
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Page 7 of 13that large quantities of NK cells are generated that kill
the tumor cells directly or augment the cytotoxic effect
of tumor directed monoclonal antibodies. The critical
findings of the studies reported herein are that (i) the
technology that was reported to successfully expand NK
cells isolated from PBMC [12,17] was also effective in
generating large numbers of NK cells from PBMC and
various elutriated cell fractions without previous isola-
tion of the CD56
+ cells, (ii) activation receptors and
other cell surface structures that mediate target cell kill-
ing are increasingly expressed on the expanded NK
cells, (iii) NK cells expanded from PBMC from patients
with solid tumors kill allogeneic and autologous cancer
cell lines by direct cytotoxicity and, importantly, mediate
ADCC to autologous tumor cell targets in the presence
of chimeric mAb and (iv) the interactions of activating
receptors DNAM-1, NKp30 and NK-p46 with cognate
ligands on the tumor target appear to mediate direct
and ADCC mediated autologous cytotoxicity in gastric
carcinoma.
For translation into the clinic it is important to
observe that besides NK cells, relatively small numbers
of NKT and T cells are expanded in this system. These
cell populations may mediate GvHD when infused
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Figure 2 Ex-vivo expanded NK cells recognize autologous gastric tumor cells through different activating receptor-ligand interactions.
PBMC from two gastric cancer patients were ex-vivo expanded for 14 days and then tested for cytolytic activity against autologous gastric
tumor cells in 4 hour
51Cr release assays. (A) Ex-vivo expanded cells from both patients (patient 1 and patient 2), but not freshly purified non-
expanded NK cells from patient 2, efficiently lysed autologous gastric tumor cells (Effector to Target Ratio 20:1). To evaluate the impact of
activating receptor-ligand interactions on autologous tumor cell lysis indicated blocking antibodies (10 μg/ml) were added during 4 hours of
incubation. (B) Cytotoxicity was reduced in the presence of DNAM-1 (P = 0.0309) and NKp30 (P = 0.0056) for patient 1 and in the presence of
NKp46 (P = 0.0003) for patient 2. In both patients autologous cytolytic activity was abrogated in the presence of all four blocking antibodies
with P = 0.0111 and P = 0.0001, respectively. Statistical analysis is based on triplicate wells of four (patient 1) and two (patient 2) experiments
performed, respectively. Error bars represent the SD. * P < 0.05. MoIgG1 indicates mouse IgG1.
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Page 8 of 13together with NK cells in adoptive allogeneic immu-
notherapy protocols. GvHD is a serious, potentially life-
threatening, condition resulting from transplanted or
infused allogeneic donor cell recognition of the recipi-
ents’ tissues as non-self, and is predominantly mediated
by CD3
+ T cells [30]. These cells are often depleted to
prevent GvHD, as could be accomplished with the cells
expanded by the protocol presented here. Depletion of
T cells from the NK cell product before administration
t ot h eh o s ti sl i k e l yt ob el e s sc r i t i c a li nt h ea u t o l o g o u s
setting.
An important observation in our studies was that the
expanded NK cells did not kill autologous and allogeneic
PBMC, an indication that despite the increase in surface
expression of activating receptors on the NK cells, the
inhibitory ligands expressed on normal PBMC were
dominant and able to control cytolytic activity against
non-malignant cells. This is further illustrated in that both
gastric tumor cell lines were susceptible to autologous
cytotoxicity despite the expression of high levels of inhibi-
tory classical and non-classical HLA class I molecules.
These data suggest that, under certain conditions, activat-
ing receptor-ligand recognition may override receptor-
ligand interactions that inhibit NK activity. Emerging data
indicates that important triggers in this interaction are
surface structures (ligand) that are expressed on cells that
have undergone malignant transformation. In addition, it
is well recognized that HLA class I expression the major
NK cell inhibitory structure, is often down regulated in
many solid tumors. In the case of autologous NK cell cyto-
toxicity against PBMC, inhibitory signals still predomi-
nated over activating signals, since no cytotoxicity of NK
cells against autologous or allogeneic PBMC was observed.
Our results indicate that the NK cells expanded and acti-
vated by the methods described do not recognize and kill
non-transformed cells.
In addition, while significantly higher levels of the
inhibitory CD94/NKG2A complex were expressed after
e x - v i v oc e l le x p a n s i o n ,i td i dn o ta f f e c tt h ep o t e n t i a lo f
autologous gastric tumor cell recognition. The CD94/
NKG2A complex is reported to directly inhibit NK cell
cytotoxicity through recognition of HLA-E [31].
Although both autologous gastric tumor cell lines did
not express HLA-E (Table 3), we can not rule out that
autologous tumor cell recognition will not be affected in
HLA-E expressing tumors.
The ligands for natural cytotoxicity receptors NKp30,
NKp44 and NKp46 are currently unknown. However;
w ep o s t u l a t et h a ta tl e a s tN K p 4 6a n dN K p 3 0m a yb e
involved in autologous gastric tumor cell recognition
since lytic activity was abrogated in the presence of
blocking antibody against these receptors. Since no sig-
nificant change was observed in NKG2D expression on
expanded NK cells, we did not directly test the involve-
ment of this activating receptor in autologous gastric
tumor cell cytotoxicity. The fact that autologous cyto-
toxicity was not completely inhibited by a combination
of anti-DNAM-1, NKp46, NKp44 and NKp30 may indi-
cate that NKG2D or other unidentified receptors may
also be involved. Importantly, the interaction between
NK cell receptors and their ligands has recently been
shown to abrogate NK cell mediated cytotoxicity of
human and mouse melanoma cell lines [32].
Of note, both tumor cell lines also expressed high
levels of Fas which is recognized to establish cell death
upon interaction with its ligand, Fas-ligand [33]. In
order to test the possibility of target cell-induced killing
of the expanded NK cells, all NK cells were evaluated
for Fas and Fas-ligand expression before and after ex-
vivo expansion. Although expanded NK cells up-
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Figure 3 Cetuximab significantly enhances cytolytic activity
and ADCC is negatively affected by inhibition of activating
receptor-ligand interactions. Ex-vivo expanded cells from cancer
patient 1 were evaluated for their ability to mediate ADCC against
autologous (patient 1) and allogeneic (TU-167 and H-358) EGFR
expressing lung cancer cells. (A) Cytolytic activity of ex-vivo
expanded cells was enhanced in the presence of Cetuximab (10 μg/
ml, black bar) but not in the presence of control human IgG1 (10
μg/ml; dotted bar) or media alone (white bar). The mean
percentage cytotoxicity is shown from triplicate wells from one
representative experiment. Error bars represent the SD. Experiment
shown represents one of two individual experiments. (B) The
addition of blocking antibodies (10 μg/ml) against DNAM-1, NKp46,
NKp44 and NKp30 (= all) significantly reduced (P = 0.0176)
Cetuximab-mediated ADCC. Statistical analysis is based on three
experiments performed. Error bars represent the SD. * P < 0.05.
HuIgG1 indicates human IgG1, Ctx; Cetuximab and moIgG1; mouse
IgG1.
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Page 9 of 13regulated high levels of Fas, they did not express Fas-
ligand (data not shown).
It has been suggested that in order to overcome self
tolerance, multiple activating receptor-ligand interac-
tions should be engaged [31]. Indeed, multiple activating
interactions appear to be involved in autologous cyto-
toxicity of tumor cells derived from patient 1 when the
inhibition of cytotoxicity, in the presence of all 4 antibo-
dies, is compared with DNAM-1 or NKp30 alone (P =
0.0356 and P = 0.0165, respectively). In contrast, no sig-
nificant additional decline in autologous cytotoxicity was
observed for patient 2 when cytolytic activity of all four
activating receptors was compared to NKp46 alone (P =
0.7359). We postulate that these data reflect variation in
expression of receptor-ligand combination in humans
that are known to be operative in the control of NK cell
cytotoxic activity. These variations include HLA and
KIR polymorphism as well as tumor type and tumor ori-
gin (e.g. primary versus metastatic tumor cells). This is
illustrated in a recent report on studies in patients with
multiple myeloma [34] where the investigators demon-
strated no specific association of autologous NK cell
cytotoxicity with a single activating NK cell receptor. In
fact, autologous cytotoxic effects were more likely
mediated by several activating NK cell receptors which
is also in agreement with a previous report [35] demon-
strating that natural cytotoxicity of resting NK cells
requires co-activation by more than one receptor.
While currently elutriated cell fraction 5 is used for
monocyte and dendritic cell-based immunotherapy ther-
apy protocols [36,37], we demonstrated that cytolytic NK
cells can be expanded from elutriated cell fractions 2, 3
and 4 regardless of the cellular content of these fractions.
However, since NK cell expansion from fraction 4 failed
in two out of four experiments, while expansion from
PBMC and elutriated cell fractions 2 and 3 was highly
successful, and considering the relative high amount of
erythrocytes in fraction 2, it may be best to primarily
Fraction 5 A PBMC
(Pre-elutriation)
Fraction 2 Fraction 3 Fraction 4
47+/-23
55+/-21
7x108
Phenotype Distribution (%)
5.1x108 1.5x108 5x109 6.9x109
Ave. Cell 
Number
32+/-28 36+/-13 39+/-9 17+/-14 CD4+
25+/-22 24+/-16 61+/-20 47+/-13 CD3+
B
2+/-3 3+/-2 3+/-2 9+/-5 5+/-4 CD19+
80+/-12 56+/-19 9+/-6 0+/-0.4 5+/-6 CD14+
2+/-3 6+/-6 8+/-7 4+/-4 4+/-4
CD3-
CD56+
3+/-6 4+/-7 15+/-11 5+/-6 6+/-7
CD3+
CD56+
3+/-4 7+/-7 22+/-12 25+/-13 11+/-7 CD8+
Figure 4 Distribution of lineage-specific phenotypic markers on PBMC and separate cell fractions obtained after counter current
elutriation. PBMC and elutriated cell fractions were stained with various lineage-specific directly-conjugated antibodies and analyzed by flow
cytometry (A). Average number of cells and phenotypic distribution (%) expressing lineage-markers in elutriated cell fractions (n = 11) (B).
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Page 10 of 13utilize fraction 3 in NK cell expansion protocols. Of note,
variability in expansion rates between donors is observed
and requires further testing to determine the extent of
this variation in the general population. Overall, these
data provide a foundation for the large-scale generation
of cytolytic NK cells from elutriated cell fractions, which
could be employed alone or in combination with other
cellular components such as dendritic cells for applica-
tion in cellular therapy of cancer.
Conclusions
In summary, the large amount of cytotoxic NK cells
generated by this ex-vivo expansion protocol provides
the numbers of NK cells that will probably be required
to be effective in the case of a large tumor burden. The
ability of the expanded cells to mediate ADCC offers
the possibility that their effect may be amplified if given
in conjunction with a cancer cell directed mAb. An
important issue to address is the ability of adoptively
transferred NK cells to home and infiltrate into solid
tumor tissue. Although the expanded NK cells only
expressed small amounts of CD62L (data not shown),
which is associated with homing into secondary tissue,
we postulate that trafficking into the tumor micro-envir-
onment may be enhanced by opsonizing tumor cells
with chimeric antibody. Clinical studies are needed to
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+CD3
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culture regardless the cellular content of these fractions. The mean percentage cytotoxicity is shown from triplicate wells from one
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Page 11 of 13confirm this hypothesis, as well as to establish the thera-
peutic benefit of infusion of large number of ex-vivo
expanded autologous NK cells.
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